# Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

> **NCT05222516** · PHASE2 · TERMINATED · sponsor: **OM Pharma SA** · enrollment: 63 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Broncho-Vaxom
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05222516
- **Lead sponsor:** OM Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-20
- **Primary completion:** 2023-07-13
- **Final completion:** 2023-07-13
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Recommendation of DSMB (futility of Endpoints)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222516, "Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05222516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*